On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
MondayOct 14, 2019 3:32 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Proprietary PCT Platform Demonstrates Ability to Discover Cancer Biomarkers in Independent Research

Pressure BioSciences’ (OTCQB: PBIO) pressure cycling technology (“PCT”) platform was recently the subject of independent research carried out by Chinese and Australian scientists in which the platform demonstrated its proficiency in processing of preserved (“FFPE”) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers (http://ibn.fm/DfmC7). An article discussing the company reads, “According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be…

Continue Reading

ThursdayOct 10, 2019 2:48 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) BaroShear K45 System Creates Water-Soluble CBD Oil

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, has developed a revolutionary CBD processing system, the BaroShear K45, which effectively solves the water solubility issue found in most of today’s oil-based CBD products. An article discussing the company reads, “Development of the BaroShear K45 system began following the company’s in-depth analysis of the CBD market, which showed a common, yet critical production issue facing CBD manufacturers – the poor water solubility of today’s oil-based CBD products means that the beneficial properties of…

Continue Reading

FridayOct 04, 2019 12:14 pm

Pressure BioSciences Inc. (PBIO) Gains Praise Amid Disclosure of Innovative Research Tool to Aid Gynecological Cancer Diagnosis, Therapy

Pressure BioSciences was described as an integral part of women’s cancer research efforts during a presentation last month at the International Gynecologic Cancer Society conference in Brazil The company’s patented pressure cycling technology provided a key link in a trio of procedures for analyzing biopsied cells Gynecologic cancers are diagnosed in the United States at a rate of nearly 100,000 women per year, and the global gynecological cancer drug market is expected to generate revenues of more than $41.8 billion by 2026 A new, novel workflow for the analysis of proteins from cancer biopsy samples was recently disclosed at a…

Continue Reading

FridayOct 04, 2019 9:59 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Initiation of Zacks Small Cap Research Coverage

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that Zacks Small Cap Research ("Zacks SCR") has initiated coverage on the company. Zacks SCR coverage maintains a specific focus on small and micro-cap companies that are believed to be undervalued and well-positioned for future growth. Zacks SCR analysts seek to identify and report on these companies, bringing to investors a unique opportunity to gain insight through its high quality (“institutional”) research for the small cap portfolio. To access the PBIO report,…

Continue Reading

TuesdayOct 01, 2019 9:52 am

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Fills Integral Role for Tumor Analyses in Novel Workflow Presented at IGCS

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its patented pressure cycling technology (“PCT”) platform was featured as an integral part of an innovative new workflow for the analysis of proteins from cancer biopsy samples. The workflow was presented during a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. According to the update, Dr. Thomas Conrads, a nationally acclaimed protein chemist and the senior director…

Continue Reading

ThursdaySep 26, 2019 12:47 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Patented PCT Platform Highlighted in 10 Separate Presentations at International Human Proteome Organization World Congress

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its patented pressure cycling technology (“PCT”) platform was prominently featured at the International Human Proteome Organization World Congress (“International HUPO”) in no less than ten separate presentations from scientists affiliated with seventeen leading research institutions worldwide. “We believe the unique value provided by our PCT platform for cancer research and diagnostics, which was broadly highlighted across ten presentations at this important international human protein conference, will help to accelerate awareness and…

Continue Reading

WednesdaySep 25, 2019 1:22 pm

Pressure BioSciences Inc.’s (PBIO) Proprietary Technology Platform Identified as Key Cancer Biomarker Research Element

Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer biomarkers Such tissues play a pivotal role in cancer research and may potentially contribute to the development of therapies and prevention protocols Cancer research is one of the more rapidly growing sectors making use of PBIO’s technology; to prepare for further expansion in the future, the company has appointed a new, highly experienced chief financial officer The company…

Continue Reading

TuesdaySep 24, 2019 12:35 pm

Pressure BioSciences Inc. (PBIO) Issues Update on Guidance for Revenue Growth and Success of Revolutionary CBD Oil Processing System

The company believes that its total revenue will more than double in 2020, led by commercialization of its revolutionary CBD oil nanoemulsification system PBIO’s BaroShear K45, based on the company’s proprietary Ultra Shear Technology (UST) platform, revolutionizes the manufacture of water-soluble, long-term, stable, highly absorbable, nanoemulsified CBD oil The worldwide CBD market is expected to reach $20 billion in sales by 2024, with competition ramping up as CBD manufacturers seek new ways to stand out PBIO has announced three pre-sales of its BaroShear K45 nanoemulsification system for making water-soluble CBD Oil Progress continues on the build-out of its GMP-compliant manufacturing…

Continue Reading

WednesdaySep 18, 2019 10:29 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Featured on Stock Day with Everett Jolley to Discuss Advancements in Proprietary Platforms

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its President and CEO Richard T. Schumacher was recently featured on The Stock Day Podcast hosted by Everett Jolley. During the interview, Schumacher discussed PBIO and the company’s recent achievements. “A year ago, PBIO had one revenue-generating division. We now have three, each based on our proprietary PCT, BaroFold, or UST platforms,” PBIO President and CEO Richard T. Schumacher said in the podcast. “Our PCT platform supports our primary business, which…

Continue Reading

TuesdaySep 17, 2019 11:40 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Adds Daniel J. Shea as Chief Financial Officer at Pivotal Time for Growth

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that Daniel J. Shea has joined the company as its senior vice president and chief financial officer effective Friday, September 13, 2019.  In the key leadership position, Shea’s responsibilities will include directing and overseeing all aspects of the company’s finance and administration functions, including financial reporting and analysis; compliance with GAAP and applicable financial and tax reporting laws and rules; forecasting and budgeting; serving as primary liaison with the company’s independent accounting…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered